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Bucillamine prevents cisplatin-induced ototoxicity
through induction of glutathione and antioxidant genes
Se-Jin Kim1,5, Joon Ho Hur2,5, Channy Park3, Hyung-Jin Kim1, Gi-Su Oh1, Joon No Lee1, Su-Jin Yoo2,
Seong-Kyu Choe1, Hong-Seob So1,4, David J Lim3, Sung K Moon3 and Raekil Park1,4
Bucillamine is used for the treatment of rheumatoid arthritis. This study investigated the protective effects of bucillamine against
cisplatin-induced damage in auditory cells, the organ of Corti from postnatal rats (P2) and adult Balb/C mice. Cisplatin increases
the catalytic activity of caspase-3 and caspase-8 proteases and the production of free radicals, which were significantly
suppressed by pretreatment with bucillamine. Bucillamine induces the intranuclear translocation of Nrf2 and thereby increases
the expression of γ-glutamylcysteine synthetase (γ-GCS) and glutathione synthetase (GSS), which further induces intracellular
antioxidant glutathione (GSH), heme oxygenase 1 (HO-1) and superoxide dismutase 2 (SOD2). However, knockdown studies
of HO-1 and SOD2 suggest that the protective effect of bucillamine against cisplatin is independent of the enzymatic activity
of HO-1 and SOD. Furthermore, pretreatment with bucillamine protects sensory hair cells on organ of Corti explants from
cisplatin-induced cytotoxicity concomitantly with inhibition of caspase-3 activation. The auditory-brainstem-evoked response of
cisplatin-injected mice shows marked increases in hearing threshold shifts, which was markedly suppressed by pretreatment with
bucillamine in vivo. Taken together, bucillamine protects sensory hair cells from cisplatin through a scavenging effect on itself,
as well as the induction of intracellular GSH.
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INTRODUCTION
Cisplatin is a commonly used platinum-containing anticancer
drug for various solid tumors, but its clinical application has
been limited because of the onset of severe side effects such as
peripheral and central neuropathies, renal insufficiency and
sensorineural hearing loss.1–3 The histopathology of cisplatin
ototoxicity studied in animals4,5 and humans6 shows that
cisplatin primarily damages the outer hair cells (OHCs) of
the organ of Corti in the inner ear,7 with gradual progress from
the basal area to the apex in the cochlear turn.8
The cytotoxic effects of cisplatin are due to the formation of
DNA adducts that lead to aberrant genetic transcription and
DNA duplication, cell cycle arrest and apoptosis.9,10 They are
also due to the accumulation of reactive oxygen species (ROS),
reactive nitrogen species and free radicals, which are often
involved in functional damage to various tissues, including the
structures within the inner ear.11–13 In cisplatin-induced
ototoxicity, ROS are formed as a consequence of antioxidant
depletion and interference with the antioxidant defense system
of the cochlea.3,14 Excessive ROS can react with a variety of
cellular components, such as DNA, proteins and unsaturated
lipids, leading to chemical modifications and metabolic and
structural alterations, which may result in cell death.15 The
active form of cell death is characterized by morphological
changes such as cell shrinkage, chromatin condensation and
DNA fragmentation. Both caspase-8 and caspase-9 participate
in a cascade that culminates in the activation of caspase-3,
which then cleaves several substrates, resulting in chromosomal
DNA fragmentation and the cellular morphological changes
characteristic of apoptosis.16 Several reports have recently
demonstrated that cisplatin ototoxicity could be alleviated by
treatment with a chemoprotectant, such as diethyldithiocarba-
mate, ebselen, flunarizine, sodium thiosulfate, glutathione
(GSH) or other sulfur-containing compounds.3,17–21 Accord-
ingly, treatment with a chemoprotectant has been shown to
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increase a number of important antioxidant enzymes in
cochlear tissues, including catalase, GSH peroxidase, GSH
reductase, GSH S-transferase, γ-glutamylcysteine synthetase
(γ-GCS) and superoxide dismutase (SOD).3,14,22,23
Oxidative stress is known to induce the expression of GSH-
synthesizing enzymes that act through the antioxidant response
element and the transcription factor Nrf2.24 Transcription
factor Nrf2 dissociates from the Keap1-Nrf2 complex and then
translocates into the nucleus, where it associates with antiox-
idant response element to enhance the expression of phase II
genes and detoxifying genes, such as catalase, GST, GPx, GR,
γ-GSC (composed of the catalytic (GCLC) and regulatory
(GCLM) subunits) and heme oxygenase-1 (HO-1).25–27 These
enzymes play important roles in protecting cells from oxidative
stress imposed by free radicals. GSH is synthesized in the
cytosol of all mammalian cells in a tightly regulated manner.
The major determinants of GSH synthesis are the availability of
cysteine, the sulfur amino acid precursor and the involvement
of two enzymatic reactions catalyzed by the rate-limiting
enzymes γ-GCS and GSS.28
Bucillamine (N-(2-mercapto-2-methylpropionyl)-L-cysteine)
is a low molecular weight thiol donor capable of rapidly
entering cells, and it is used to treat rheumatoid arthritis.29
Bucillamine can also directly scavenge peroxides and is shown
to be 4-fold more effective than N-acetylcysteine (NAC) in
preventing ischemia-reperfusion injury from in vitro studies30
and 16-fold more effective from in vivo studies.31 In experi-
mental studies, bucillamine, like the cysteine derivative NAC,
inhibited liver ischemia-reperfusion injury and raised the
survival rate after transplant by increasing GSH levels in the
liver and decreasing oxidized GSH levels in both the liver and
blood.32 In recent studies using murine Hepa 1-6 and human
HepG2 hepatoma cells, the mechanisms of action of bucilla-
mine have been mainly described as donating thiol groups to
GSH and significantly increasing the GSH content by two to
threefold, as well as inducing the expression of the γ-GCS
catalytic subunit (GCLC), the rate-limiting enzyme of GSH
biosynthesis and the multidrug-resistance-associated protein
(Mrp2), which mediates the excretion of GSH.33 However, the
molecular mechanism of bucillamine to mediate the beneficial
effect has not been fully elucidated.
In this study, we investigated for the first time the antiox-
idant and cytoprotective roles of bucillamine against cisplatin-
induced cytotoxicity in auditory cells in vitro and organ of Corti
explants ex vivo. Furthermore, we also investigated in vivo
effects of bucillamine on auditory-brainstem-evoked response
(ABR) threshold changes in cisplatin-treated Balb/C mice.
MATERIALS AND METHODS
Chemicals
Cisplatin and 3-(4,5-dimethylthiazol-2-yl)-2, 5-diphenyl-tetrazolium
bromide (MTT) were purchased from Sigma Chemical Co (St Louis,
MO, USA). Bucillamine was a generous gift from Kuhnil Pharma-
ceutical Co. (Seoul, Korea). Genomic DNA purification kits were
obtained from Promega (Madison, WI, USA). Plastic culture wares
were purchased from Falcon, Inc. (Becton Dickinson Biotech, Lincoln,
IL, USA). Dulbecco's modified essential medium (DMEM), fetal
bovine serum (FBS) and other tissue culture reagents were purchased
from Life Technologies, Inc. (Gaithersburg, MD, USA). Various
antibodies, including anti-GCLM, anti-GCLC, anti-GSS, anti-Nrf2,
anti-SOD1, anti-SOD2 and anti-β-actin antibodies were obtained from
Santa Cruz Biotechnology (Santa Cruz, CA, USA). The anti-HO-1
monoclonal antibody was purchased from Stressgen (Ann Arbor, MI,
USA). The active form of anti-caspase-3 was purchased from Abcam
(Cambridge, UK).
Animals
Twenty healthy Balb/C male mice (weight 20± 1 g) were used in this
study, and their hearing ability was confirmed to be within the normal
range by ABR measurements. Animals were randomly divided into
four groups—control mice (0.9% saline solution), mice injected with
bucillamine (100mg kg− 1 per day) alone for 4 days, mice injected
with cisplatin (4mg kg− 1 per day) alone for 4 days, and mice injected
with bucillamine and cisplatin—and were used to carry out ABR
studies after 3 days following the cisplatin injection. Stock solutions of
bucillamine (5mgml− 1) were prepared in normal saline (pH 7.4)
with equimolar NaOH and sterilized using a 0.22-μm syringe filter.
The mice were subsequently injected with bucillamine twice a day
(100mg kg− 1 per day, intraperitoneally (i.p.)); control mice received
saline solution. This study was reviewed by the Committee for Ethics
in Animal Experiments of the Wonkwang University and carried out
under Korean law and the Guidelines for Animal Experiments.
Cell culture and viability assays
HEI-OC1 auditory cells were maintained in high-glucose DMEM
containing 10% FBS for characterization. For the experiments
described below, HEI-OC1 cells were cultured under the following
permissive conditions: 33 °C, 5% CO2 in DMEM supplemented with
10% FBS. Cells (5× 104 per well in 24-well plates) were incubated with
various concentrations of bucillamine (0.25~ 4mM) and cisplatin
(20 μM) for 30 h. To determine cell viability, MTT (0.5mgml− 1
phosphate-buffered saline (PBS)) solution was added to the cell
culture media (1/100, v/v) for 4 h and washed with PBS (pH 7.4).
Dimethyl sulfoxide was added to each well to solubilize the formazan
crystals formed in viable cells. The optical density of each culture well
was measured by using a microtiter plate reader (Molecular Devices
Co., Sunnyvale, CA, USA) at 590 nm. The optical density of control
cells was taken as 100% viability.
DAPI staining of nuclei
The nuclei of HEI-OC1 cells were stained with the chromatin dye
4′-6-diamidino-2-phenylindole (DAPI). Cells were fixed with 3.7%
paraformaldehyde for 10min at room temperature, washed twice with
PBS and then incubated with 10 μM DAPI in PBS at room temperature
for 30min. After three washes, cells were observed under a fluores-
cence microscope (IX71, Olympus, Tokyo, Japan).
Genomic DNA preparation and electrophoresis
Genomic DNA was isolated using the Wizard genomic DNA
purification kit (Promega) and purified by serial ethanol precipita-
tions. Five micrograms of isolated genomic DNA were subjected to
1.5% agarose gel electrophoresis at 50 V for 3 h. DNA was visualized
under UV light following staining with ethidium bromide.
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Colorimetric caspase-3 and caspase-8 activity assay
Colorimetric assay kits (R&D Systems, Inc., Minneapolis, MN, USA)
were used to measure the enzyme activities of caspase-3 and caspase-8
according to the manufacturer's instructions. After 24 h treatment with
cisplatin in the presence or absence of bucillamine, the medium was
gently removed and discarded, while the cell pellet was lysed by the
addition of the lysis buffer. The cell lysates were incubated on ice for
10min and centrifuged at 10 000× g for 1min at 4 °C. The supernatant
was then transferred to a new tube to determine caspase activity.
Extracts (50 μl) from cells treated with cisplatin in the presence or
absence of bucillamine were added to 50 μl of reaction buffer and 5 μl
of caspase-3 (DEVD-pNA) or caspase-8 (IETD-pNA) colorimetric
substrate. Each mixture was placed in wells of a 96-well plate and
incubated for 1 h at 37 °C. Absorbance at 405 nm was measured using
a microtiter plate reader (Molecular Devices Co., Sunnyvale, CA,
USA). Caspase activity was normalized to micrograms of protein using
a Bio-Rad protein assay kit (Bio-Rad Co., Hercules, CA, USA).
Preparation of cytosolic and nuclear fractions
Cells were washed with ice-cold PBS, scraped and centrifuged at 1000× g
for 5min at 4 °C. The cell pellet was resuspended in 200 μl of lysis buffer
(10mM HEPES (pH 7.9), 1.5mM MgCl2, 0.5mM dithiothreitol and
0.5mM phenylmethylsulfonyl fluoride) and incubated on ice for 15min.
At the end of the incubation, 10 μl of 10% NP-40 were added and the
tube was vortexed for 10 s. After centrifugation at 13 000× g for 1min at
4 °C, the supernatant (cytosolic extracts) was collected and stored at
− 80 °C, and the pellet was further processed to obtain a nuclear extract.
The pellet was resuspended in extraction buffer (5mM HEPES (pH 7.9),
1.5mM MgCl2, 0.5mM phenylmethylsulfonyl fluoride, 0.2mM EDTA,
0.5mM dithiothreitol and 25% glycerol (vol/vol)) and incubated for
30min at 4 °C. The supernatant (nuclear extracts) was aliquoted and
stored at − 80 °C until used for western blot analysis. The protein
concentration was determined by the Lowry method.
Western blotting
Cell extracts were separated by 10% SDS-PAGE under reducing
conditions and transferred to a nitrocellulose membrane. Nonspecific
proteins were blocked with 5% skim milk in TBS-T (25mM Tris
(pH 7.6), 138mM NaCl and 0.05% Tween-20) for 1 h and probed
with primary antibodies (diluted 1:1000–1:5000). After a series of
washes, the membrane was incubated with secondary antibody
(diluted 1:2000–1:10 000) conjugated with horseradish peroxidase.
The immunoreactive signal was detected using an enhanced chemi-
luminescent detection system. The active form of caspase-3 antibody
(1:1000 dilution; Abcam) was used to recognize the large fragment of
cleaved caspase-3 (17 kDa). The protein concentration was estimated
according to the protocol from Bio-Rad Laboratories, Inc., using
1mgml− 1 bovine serum albumin as the standard.
Measurement of intracellular ROS and nitric oxide levels
HEI-OC1 cells were cultured overnight and then treated with 20 μM
cisplatin in the presence or absence of bucillamine for 24 h.
Intracellular ROS levels were measured using the fluorescent dye
2′,7′-dichlorofluorescein diacetate (DCF-DA, Eastman Kodak, Roche-
ster, NY, USA). In the presence of an oxidant, DCF-DA is converted
into the highly fluorescent DCF. For the ROS assay, the cells were
treated with 10 μM DCF-DA and were further incubated for 1 h at
37 °C. Intracellular nitric oxide (NO) production by HEI-OC1 cells was
assessed by measuring the fluorescence of 4-amino-5-methylamino-
2′,7′-difluorofluorescein, a specific NO probe (Molecular Probes, Inc.,
Eugene, OR, USA). 4-Amino-5-methylamino-2′,7′-difluorofluorescein
is a cell-permeable, NO-sensitive dye that is virtually nonfluorescent
until it reacts with NO to form a fluorescent benzotriazole. For the NO
assay, the cells were treated with 10 μM DAF-FA and were further
incubated for 1 h at 37 °C. The cells were rinsed with PBS and detected
through flow cytometric analysis. Fluorescence intensity was measured
using a BD FACSCalibur Flow Cytometer System (BD Biosciences,
San Jose, CA, USA). For each analysis, 20 000 events were collected
and analyzed using FL1 (DCF-DA and 4-amino-5-methylamino-2′,
7′-difluorofluorescein) channel. Data were analyzed using BD Cell
Quest Software (BD Biosciences).
Measurement of reduced GSH contents
Intracellular GSH content was measured by using a Glutathione Assay
Kit (Sigma) according to the manufacturer's instruction with minor
modifications. To analyze the effect of bucillamine on intracellular
GSH concentration, HEI-OC1 cells seeded in 100-mm dishes were
treated with 20 μM cisplatin in the presence or absence of 2mM
bucillamine. After experimental treatment, cells were harvested and
washed with ice-cold PBS (0.24 g l− 1 KH2PO4, 1.44 g l
− 1 Na2HPO4,
0.2 g l− 1 KCl and 8.0 g l− 1 NaCl (pH 7.4)). Cells were centrifuged at
600× g to obtain a cell pellet, and the supernatant was removed. Cells
were then suspended in 0.2ml of 0.1 M potassium phosphate buffers
(pH 7.0) containing 1mM EDTA. The cell suspension was sonicated to
obtain the cell homogenate; the resulting homogenate (0.2 ml lysate)
was transferred to microcentrifuge tubes, except for a small portion
that was saved for protein quantification. An equal volume of 5%
sulfosalicylic acid was added to the cell extract (0.2ml), and the
precipitated proteins were sedimented by centrifugation at 10 000× g
for 10min at 4 °C. The volume of the supernatant was measured, and
the original volume for total GSH was used according to the
manufacturer's instruction. For microplate reader determination,
10 μl of the cell extract supernatant or of the standard GSH solution
was mixed with 150 μl of the working mixture, and then 50 μl of
0.16mgml− 1 NADPH solution was added with a multichannel pipette.
The final concentration of the components in the reaction mixture was
95mM potassium phosphate buffer (pH 7.0), 0.95mM EDTA, 0.038
mgml− 1 NADPH, 0.031mg/MlDTNB (5,5′-dithio-bis(2-nitrobenzoic
acid)), 0.115 units ml− 1 GSH reductase and 0.24% 5-sulfosalicylic acid.
The total GSH content was expressed as nmol mg− 1 protein. Values
were represented as the mean (s.d.) of triplicate samples.
Analysis of mRNA levels by semi-quantitative reverse
transcription-PCR
Cells were plated on 60-mm dishes to a density of 1 × 105, and total
cellular RNA was extracted using TRIzol reagent (Invitrogen, Carlsbad,
CA, USA) according to the manufacturer's protocol. Equal amounts
(1 μg) of total RNA were treated with reverse transcriptase (Promega,
Madison, WI, USA) in the presence of 20 units of RNasin (Promega).
Amplification of cDNA was performed in 20 μl reactions containing
10 μl of 2 ×Taq Premix I (SolGent Co., Daejeon, Korea) and 2 μl of
each primer (5 pmol). To ensure that equal amounts of cDNA were
added to the PCRs, an internal standard was amplified using the
β-actin gene oligonucleotides (F5′-GTGGGCCGCTCTAGGCACCAA
-3′ and R5′-CTCTTTGATGTCACGCACGATTTC-3′). Transcription
factor Nrf2 was amplified using synthetic primers (F5′-AGCTC
TCTGGAGGCAGCCATGAC-3′ and R5′-GACTCCACGGAGTG
CTCTGG-3′). GSH redox system-related genes and phase II antiox-
idant genes were amplified using synthetic primers as follows: GSS,
F5′-CCCGCCTCCGAGCCACCTT-3′ and R5′-CCACTCCTGCCGC
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CACACCT-3′; GCLC, F5′-ACAAGCACCCCCGCTTCGGT-3′ and
R5′-CTCCAGGCCTCTCTCCTCCC-3′; GCLM, F5′-ACCTGGCCTC
CTGCTGTGTG-3′ and R5′-GGTCGGTGAGCTGTGGGTGT-3′. The
amplified PCR products were resolved by 1.0% agarose gel electro-
phoresis, stained with ethidium bromide, and visualized under UV.
Quantitative real-time PCR
First-strand cDNAs obtained from total RNAs were used for quanti-
tative real-time PCR. Quantitative real-time PCR was performed with
Lightcycler Nano (Roche, Indianapolis, IN, USA) using the FastStart
Essential DNA Green Master (Roche Diagnostics, GmbH, Mannheim,
Germany). The primers used were as follows: GAPDH, F5′-TGGT
CCCGTAGACAAAATGG-3′ and R5′-TTGAGGTCAATGAAGGGG
TC-3′; HO-1, F5′-ACAACCAGTGAGTGGAGCCT-3′ and R5′-TCA
AGGCCTCAGACAAATCC-3′; Nrf2, F5′-CCTCTGCTGCAAGTAG
CCTC-3′ and R5′-TGCCTCCAAAGGATGTCAAT-3′; GSS, F5′-GAA
GCAGCTCGAAGAACTGG-3′ and R5′-AGCACTGGGTACTGGTG
AGG-3′; GCLC, F5′-CTGCACATCTACCACGCAGT-3′ and R5′-GTC
TCAAGAACATCGCCTCC-3′; GCLM, F5′-CGGGAACCTGCTCAAC
TG-3′ and R5′-CCAAAACATCTGGAAACTCCC-3′; SOD1, F5′-AC
CATCCACTTCGAGCAGAA-3′ and R5′-AAAATGAGGTCCTGCAC
TGG-3′; SOD2, F5′-AACTCAGGTCGCTCTTCAGC-3′ and R5′-GCT
TGATAGCCTCCAGCAAC-3′. GAPDH expression was used to
normalize mRNA levels. The evaluation of relative mRNA levels
among the treatment groups was carried out using the ΔΔCT method.
Data are presented as relative fold changes compared with the
control group.
Transfection of small interference RNA in HEI-OC1 cells
Predesigned small interference RNAs (siRNAs) against mouse HO-1
(sc-35555), SOD2 (sc-416560) and control siRNA (sc-37007) were
purchased from Santa Cruz Biotechnology. The sense strands of
siRNAs against HO-1 and SOD2 are a pool of three target-specific
siRNAs designed for known gene expression. Cells were transfected
with double-stranded siRNAs (0.5 μgml− 1) in antibiotic- and serum-
free medium for 6 h by using the X-tremeGENE siRNA transfection
reagent according to the protocol provided by manufacturer (Roche
Applied Sciences, Indianapolis, IN, USA) and recovered by the
addition of fresh medium containing 10% FBS for 12 h. Next, these
cells were treated with 20 μM cisplatin in the presence or absence of
bucillamine for 24 h. The expression of HO-1 and SOD2 was
confirmed by western blot analysis (anti-HO-1 and anti-SOD2
antibodies) and reverse transcription-PCR (RT–PCR) (HO-1 and
SOD-2 primer). Blots were reprobed with a goat anti-β-actin antibody
for a protein loading control, and RT–PCR was performed with
β-actin primer as a control.
Organotypic cultures of organ of Corti explants
Sprague-Dawley rats were killed on postnatal day 2 (P2), and the
cochlea were carefully dissected. The stria vascularis and the spiral
ligament were dissected away, leaving the organ of Corti. For further
study, the organ of Corti was dissected into three regions of the apical,
middle and basal turns. Cochlear explants were treated with DMEM
containing glucose (4.5 g l− 1) and 10% FBS during the stationary
phase of cell growth at 12 h post dissection. Cochlear explants were
pretreated with 2mM bucillamine for 1 h before the addition of 30 μM
cisplatin. Following the addition of cisplatin and 2mM bucillamine or
30 μM cisplatin-only treatments, the cells were incubated for 30 h at
37 °C, 5% CO2. The control group, maintained with serum containing
DMEM only, was cultured concurrently with the experimental groups.
At the end of the experiment, the cultures were prepared for
histological analysis. Organotypic cultures of the organ of Corti were
fixed in 4% paraformaldehyde in PBS at room temperature for
15min. The specimens were rinsed with PBS, incubated in 0.25%
Triton X-100 for 2min and immersed in tetramethylrhodamine
isothiocyanate-labeled phalloidin (Sigma, 1:100 diluted) in PBS for
20min. After rinsing three times with PBS, the specimens were
examined under a fluorescence microscope with appropriate filters for
tetramethylrhodamine isothiocyanate (excitation 540–545 nm, emis-
sion 570–573 nm).
Auditory-brainstem-evoked response
ABR measurement was performed with TDT system II (Tucker Davies
Technologies, Gainesville, FL, USA) and standard modular system
using TDT Bio-Sigsoftware. Before ABR measurement, the animals
were anesthetized intramuscularly with a mixture of xylazine
(10mg kg− 1) and ketamine (40mg kg− 1) and placed in an electrically
shielded, double-walled radiofrequency-shielded sound booth. An
earphone (Etymotic ER-2, Etymotic Research, Elk Grove Village, IL,
USA) was placed directly into the ear canal. An active electrode lead
was placed at the vertex, the reference electrode at the test ear and the
ground electrode below the neck muscle. Auditory stimuli were
recorded in response to 100-μs clicks and 10-ms tone burst with a
rise/fall time of 1 msat 4, 8, 16 and 32 kHz. The sound intensity was
progressively decreased in 10-dB steps and 5-dB steps (click). The ABR
threshold was defined as the lowest stimulus intensity that produced a
replicable waveform response. Weight loss was monitored daily for
8 days after all reagent (cisplatin, bucillamine, saline) treatments, and
mice were supplied with 0.6 ml saline solution (i.p. injection, twice a
day) to prevent death from dehydration.
Statistical analysis
Each experiment was performed at least three times, and all values are
represented as the means (s.d.) of triplicates. One-way analysis of
variance was used to analyze the statistical significance of the results.
All analyses were performed using the Origin Pro 7.5 statistical
software program. P values less than 0.05 were considered statistically
significant.
RESULTS
Bucillamine protects HEI-OC1 cells from cisplatin-induced
apoptotic death.
To investigate effects of bucillamine on cisplatin-induced
cytotoxicity, we first analyzed whether bucillamine affects the
viability of HEI-OC1 cells by using MTT reduction assay.
Bucillamine alone at various concentrations (0.25–4mM) had
no significant effect on cell viability (data not shown), whereas
treatment with 20 μM cisplatin significantly decreased cell
viability compared with control HEI-OC1 cells maintained
with medium only (Figure 1a). We further found that
pretreatment with bucillamine followed by cisplatin (20 μM)
prevented the cytotoxicity caused by cisplatin in a dose-
dependent manner. To determine whether cisplatin-induced
reduction in cell viability is due to apoptosis, we examined the
internucleosomal cleavage of DNA in HEI-OC1 cells after
treatment with cisplatin in the presence or absence of
bucillamine (Figure 1b). Treatment with cisplatin resulted in
DNA fragmentation, visible as a ladder pattern characteristic of
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apoptotic cell death, whereas pretreatment with bucillamine
dose-dependently decreased the ladder pattern of DNA clea-
vage in cisplatin-treated HEI-OC1 cells. Also, morphological
change of HEI-OC1 cells was examined after treatment with
cisplatin in the presence or absence of 2 mM bucillamine
(Figure 1c). DAPI staining showed the presence of apoptotic
bodies in the nuclei of HEI-OC1 cells after treatment with
cisplatin, but did not observ in cells maintained with either
medium or bucillamine. Moreover, microscopic analysis
showed that cisplatin-treated cells were variable in size, had
protuberances that resulted in a spindle-like shape (indicated as
an arrow). The cisplatin-treated cells were also shrunken, with
their membranes rounded up, and they lost contact with either
neighboring cells or the culture plate. However, pretreatment
with bucillamine preserved cells to maintain normal morphol-
ogy and their tightly attached form similar to control cells. To
quantify the kinetics of both apoptotic events and cell cycle
analysis, FACS analysis was performed with propidium iodide
staining (Figure 1d). After treatment with cisplatin, the
percentage of cells in the sub-G0/G1 phase increased up to
16.09% from 1.8% of control culture, whereas pretreatment
with bucillamine markedly inhibited cisplatin-induced
apoptotic cell death and reduced the percentage of cells in
the sub-G0/G1 phase to 2.42%. The percentage of cells in the
sub-G0/G1 phase with 2 mM bucillamine-treated cells was
2.17%. These results suggest that pretreatment with bucilla-
mine prevented apoptotic cell death induced by cisplatin.
Bucillamine suppresses the activation of caspase-3 and
caspase-8 in cisplatin-treated HEI-OC1 cells.
We tested whether caspase-3 was involved in cisplatin-induced
apoptosis using a caspase-3 colorimetric assay (R&D Systems).
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Figure 1 Pretreatment with bucillamine protects HEI-OC1 cells from cisplatin-induced apoptosis. (a) Cells were pretreated with various
concentrations of bucillamine for 1 h followed by the addition of 20 μM cisplatin for 30 h, and cell viability was measured by MTT assays.
(b) Genomic DNA isolated from cells, treated as indicated, was subject to 1.5% agarose gel electrophoresis. (c) Cells were stained with
DAPI and observed under a fluorescence microscope to detect morphological changes in the nuclei. (d) Cells were treated with 2mM
bucillamine and the cell cycle was analyzed, according to sub-G0/G1 fraction ratio by flow cytometry. The results are shown as the mean %
(s.d.) of triplicate experiments. * Indicates a significant difference between cells treated with medium alone, cisplatin or cisplatin plus
bucillamine (Po0.01 by one-way analysis of variance test).
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Treatment with cisplatin (20 μM) significantly increased the
catalytic activity of caspase-3 (4.14-fold compared with control,
Po0.01), which was markedly decreased by bucillamine
(2mM) (Figure 2a). Bucillamine alone did not exert any
significant effect on caspase-3 activity. To analyze one of the
upstream activators of caspase-3, the enzymatic activity of
caspase-8 was measured (Figure 2b). We found that treatment
with cisplatin alone significantly increased caspase-8 activity,
whereas pretreatment with bucillamine markedly decreased the
catalytic activity of caspase-8 to the level similar to the control
or bucillamine alone, suggesting that activities of both caspase-
3 and -8 are downregulated by bucillamine in the presence of
cisplatin.
Next, caspase-3 activation was examined microscopically by
immunofluorescence at a single-cell level as well as by western
blot analysis using an antibody specific for the activated form
of caspase-3 (Figures 3a and b). Upon caspase-3 activation,
32 kDa procaspase is cleaved into 17 kDa active form by
proteolytic cleavage.34 Treatment of cells with cisplatin
(20 μM) for 24 h resulted in an increase of the fluorescent
signal in the cytosol (Figure 3a) and appearance of 17 kDa
fragment detected by western blot (Figure 3b). In contrast,
pretreatment with 2 mM bucillamine abolished the cisplatin-
induced activation of caspase-3.
Bucillamine suppresses the generation of ROS and NO in
cisplatin-treated HEI-OC1 cells.
To analyze ROS-scavenging effects of bucillamine, we exam-
ined the intracellular ROS levels by flow cytometry by using an
oxidation-sensitive fluorescent probe, DCF-DA, in HEI-OC1
cells (Figure 4a). The basal level of DCF-DA oxidation was
observed in control cells, which was markedly suppressed by
bucillamine (2 mM). To determine whether bucillamine sup-
presses ROS generation induced by cisplatin, intracellular levels
of hydroxyl radicals and NO were measured using the
fluorescent probes DCF-DA and 4-amino-5-methylamino-
2′,7′-difluorofluorescein, respectively, (Figure 4b). The basal
level of intracellular oxidant produced by HEI-OC1 cells was
defined by a probe intensity of 102 and bucillamine alone
decreased hydroxyl radicals, shown as a fluorescent intensity of
DCF, up to 34.6% and NO to 26.5% compared with the
control (Figure 4c). However, treatment with cisplatin for 24 h
markedly increased hydroxyl radicals up to 192.6% and NO
up to 183.7% compared with control levels. In contrast,
pretreatment with bucillamine for 1 h completely blocked the
generation of hydroxyl radicals and NO by cisplatin.
Bucillamine induces the expression and nuclear
translocation of Nrf2
Because Nrf2 is a key transcription factor in regulating the
expression of phase II detoxifying and antioxidant genes, we
first examined nuclear translocation of Nrf2 by immunofluor-
escence (Figure 5a). In the fluorescent microscopic view, Nrf2
was mainly located in cytosol, whereas treatment with cisplatin
slightly increased nuclear Nrf2 compared with untreated
controls. However, pretreatment with bucillamine markedly
increased translocation of Nrf2 into the nucleus in the presence
or absence of cisplatin. Western blot analysis of cytosolic and
nuclear fractions clearly demonstrated that nuclear fraction of
Nrf2 was time-dependently increased in expression by pre-
treatment with bucillamine in the presence of cisplatin
(Figure 5b). As endogenous Nrf2 is mainly found in the
cytoplasm under normal conditions, we did not find much
effect on the cytoplasmic fraction of Nrf2 with either cisplatin
or bucillamine treatment. Next, Nrf2 expression was tested by
RT-PCR and quantitative real-time PCR. As shown in Figure
5c and d, pretreatment with bucillamine resulted in a time-
dependent increase of the expression levels of Nrf2 mRNA.
Bucillamine increases intracellular GSH level by inducting
GSH synthesis genes
Because bucillamine induces Nrf2 nuclear translocation
(Figure 5), we examined whether expression of Nrf2 target
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Figure 2 Bucillamine suppresses the catalytic activation of
caspase-3 and caspase-8 in HEI-OC1 cells treated with cisplatin.
Cells were pretreated with 2mM bucillamine for 1 h, followed by
the addition of 20 μM cisplatin for 24 h. Cells lysates were reacted
with Ac-IETD-pNA and Ac-DEVD-pNA, the p-NA-conjugated specific
substrates for caspase-3 (a) and caspase-8 (b), respectively.
Enzymatic activity assays for caspases were performed according
to colorimetric assay at 405 nm absorbance using a
spectrophotometer. Data are shown as the mean (s.d.) of triplicate
experiments. *Po0.01 compared with control.
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genes related to redox regulation of the GSH system, including
γ-GCS (GCLC and GCLM subunits; a rate-limiting enzyme
of GSH synthesis) and GSS. Treatment with bucillamine
significantly increased the expression of GCLC and modifier
subunit (GCLM) compared with cisplatin-treated cells (Figures
6a and b). However, bucillamine slightly increased mRNA
levels of GSS compared with cisplatin-treated cells using RT-
PCR at the indicated time point and quantitative RT-PCR at
12 h. Western blot analysis showed that bucillamine
significantly increased the expression of GCLC, but not GSS
and GCLM, after cisplatin treatment for 24 h (Figure 6c). We
next examined whether pretreatment with bucillamine
modulated the intracellular GSH contents in cisplatin-treated
HEI-OC1 cells. GSH concentration in cisplatin-treated cells
decreased from a control value of 26.03± 1.34 (mean± s.e.m.,
n= 6) to 16.47± 1.36 nmol mg− 1 protein (n= 6, Po0.01).
Pretreatment with bucillamine prevented the depletion of
GSH (36.34± 1.15 nmolmg− 1 protein) (n= 6, Po0.01)
Control
Cisplatin
(20 µM)
Bucillamine
+ Cisplatin
Bucillamine
(2 mM)
Light microscopy Active caspase-3
Activated
caspase-3
Cisplatin (20 µM)
Bucillamine (2 mM)
- + + -
- - + +
Figure 3 Bucillamine suppresses cisplatin-induced caspase-3 activation in HEI-OC1 cells. (a) Cells were pretreated with 2mM bucillamine
for 1 h followed by the addition of 20 μM cisplatin for 24 h. Cells were then washed and fixed, and the active form of caspase-3 was
determined by immunofluorescence. Pictures were taken using a fluorescence microscope (original magnification, ×600). (b) Equal
amounts of total proteins (50 μg per lane) from cell lysate of the above experimental conditions were prepared, and subject to SDS-PAGE
and western blot analyses.
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compared with cells treated with cisplatin alone. Notably,
bucillamine alone significantly increased intracellular GSH
contents (45.75± 1.76 nmolmg− 1, n= 6, Po0.01) compared
with the control (Figure 6d). These results indicate that
pretreatment with bucillamine significantly increased intracel-
lular GSH contents by the induction of GSH synthesis genes via
Nrf2 activation.
Bucillamine induces expression of phase II detoxification
enzymes in HEI-OC1 cells
The transcription factor Nrf2, a major regulator of genes
encoding phase II detoxifying enzymes, is essential in protect-
ing cells from oxidative damage. We found that mRNA
expression of antioxidant genes, including HO-1, Cu/Zn
SOD1 and MnSOD2 significantly increased after pretreatment
with bucillamine compared with cisplatin-treated cells at 12 h
using quantitative RT-PCR analysis (Figure 7a). Interestingly,
bucillamine alone also induced high mRNA levels of these
genes. We also examined protein levels of HO-1, SOD1 and
SOD2 enzymes in response to cisplatin treatment in the presence
or absence of bucillamine at 24 h. Consistent with mRNA
expression, bucillamine markedly induced the expression of
HO-1, SOD1 and SOD2 enzymes compared with cells treated
with cisplatin alone. Bucillamine alone also significantly
increased the protein levels of these enzymes (Figure 7b).
siRNA knockdown of phase II HO-1 and SOD2 enzymes
does not attenuate the protective effects of bucillamine
Because phase II enzymes, such as HO-1 and SOD2, are well-
known antioxidant enzymes, we determined whether knock-
down of cytosolic HO-1 or mitochondrial SOD2 enzyme can
regulate cisplatin-induced cell death and whether the protective
effects of bucillamine against cisplatin is mediated by these
enzymes. Transfection with siRNA HO-1 (47.46%), siRNA
SOD2 (45.47%) and both (41.84%) slightly increased the
sensitivity of cytotoxicity in response to cisplatin compared
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Figure 4 Bucillamine scavenges ROS generated by cisplatin in HEI-OC1 cells. (a) To test spontaneous production of intracellular ROS,
cells were treated with DCF-DA, a ROS-specific fluorescence dye, for 1 h and then, fluorescence intensity was measured using a flow
cytometer. (b) Cells were pretreated with 2mM bucillamine followed by the addition of 20 μM cisplatin for 24 h. Then, cells were incubated
with the dyes, including DCF-DA for hydroxyl radical and 4-amino-5-methylamino-2′,7′-difluorofluorescein for nitric oxides. After 1 h, the
fluorescence intensity was measured using a flow cytometer. (c) Relative intensities from FACS analyses are shown in the bar graph.
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Figure 5 Bucillamine induces the subcellular localization of Nrf2 in HEI-OC1 cells treated with cisplatin. (a) Cells grown in chamber slides
were pretreated with 2mM bucillamine for 1 h followed by the addition of 20 μM cisplatin for 12 h. Subcellular localization of Nrf2 was
detected by indirect immunofluorescence staining with anti-Nrf2 antibodies followed by Alexa488–conjugated second antibodies (green).
The nucleus (left panel) was stained with DAPI (blue), and fluorescent images were obtained. (b) Cytosolic (CE) and nuclear (NE) extracts
from cells were separated on 12% SDS-PAGE and subjected to western blot analysis using anti-Nrf2 antibody. (c) Quantitative real-time
PCR was carried out to determine the relative expression level of Nrf2 at 3 h. (d) Total RNA from cells was isolated with TRIzol reagent,
cDNA was generated using reverse transcriptase, and PCR was performed to determine expression levels of Nrf2 at indicated time points.
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with cells treated with cisplatin alone (54.34%) and the control
scramble siRNA (51.46%) (Figure 8a). Pretreatment with
bucillamine significantly recovered the protective effects against
cisplatin in cells transfected with siRNA HO-1(79.22%), siRNA
SOD2 (76.93%) or both (69.31%), respectively (Figure 8a).
Therefore, we performed a western blot to determine whether
knockdown of HO-1, SOD2 or both induces the catalytic
activation of caspase-3 (Figure 8b). We found that knockdown
of antioxidants HO-1, SOD2 or both weakly increased the
active form of caspase-3 in cisplatin-treated HEI-OC1 cells,
confirming the cell viability assay. In contrast, pretreatment
with bucillamine significantly inhibited caspase-3 activation
irrespective of knockdown of HO-1, SOD2 or both, indicating
that bucillamine-mediated protective effects do not necessarily
require the enzymatic activity of HO-1 and SOD2 in response
to cisplatin.
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Figure 6 Bucillamine increases expression of γ-GCS and GSS in HEI-OC1 cells. (a) Cells were pretreated with 2mM bucillamine for 1 h
followed by the addition of 20 μM cisplatin for different time intervals as indicated. Total RNA was isolated and cDNA was synthesized by
reverse transcription. cDNAs of γ-glutamylcysteine synthetase (γ-GCS: GCLC and GCLM) and glutathione synthetase (GSS) were amplified
using specific primer sets. (b) mRNA expression levels of GSS, GCLC and GCLM were analyzed by quantitative real-time PCR at 12 h.
(c) Cell lysates were collected, electrophoresed through an SDS-polyacrylamide gel, and subject to immunoblot analysis with antibodies
against γ-GCS (GCLC and GCLM) or GSS. The protein and mRNA levels of β-actin were used as controls. (d) Intracellular GSH content was
measured by using a Glutathione Assay Kit. Total GSH contents were expressed as nmolmg−1 protein. Values are represented as the mean
(s.d.) of triplicate samples. *Po0.01 compared with control.
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Bucillamine prevents cisplatin-induced cell death and
hearing loss
To confirm the protective effects of bucillamine on sensory hair
cells from the organ of Corti explants against cisplatin, cochlear
explants of 2-day neonatal (P2) rats were isolated, dissected
into three parts (apex, middle and basal) and cultured in 4-well
plates. Cochlear explants treated with cisplatin in the presence
or absence of 2 mM bucillamine were stained with Alexa
568-phalloidin to label the stereocilia of sensory hair cells.
We found that cochlear cultures treated with cisplatin resulted
in disorganized sensory hair cell rows and loss of stereocilia in
the majority of sensory hair cells (Figure 9a). In contrast,
bucillamine-pretreated cochlear cultures showed three orderly
rows of OHCs and one row of inner hair cells, similar to
control (not shown).
To determine the protective effects of bucillamine in vivo, we
measured ABR thresholds in control mice (saline solution),
mice injected with cisplatin (16 mg kg− 1 per 4 days) in the
presence or absence of bucillamine, and mice injected with
bucillamine alone (400mg kg− 1 per 4 days) (Figure 9b and c).
For 3 days following cisplatin exposure, ABR thresholds
increased significantly in all frequencies (2, 4, 8, 16 and
32 kHz tones and click), and the changes of each values were
statistically significant compared with the control group
(Po0.05). The increase in ABR thresholds was greater for
the higher-frequency stimuli at 16 and 32 kHz than at 4 and
8 kHz. In contrast, pretreatment with bucillamine plus cisplatin
did not show significant ABR threshold changes compared with
the saline-treated control group. Importantly, ABR thresholds
in the bucillamine plus cisplatin-treated group were
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Figure 7 Bucillamine induces phase II antioxidants and detoxifying enzymes in HEI-OC1 cells treated with cisplatin. (a) Cells were
pretreated with 2mM bucillamine for 1 h followed by the addition of 20 μM cisplatin at 12 h. Phase II antioxidant genes (HO-1, SOD1 and
SOD2) from total RNA were amplified using specific primer sets. Expression levels of HO-1, SOD1 and SOD2 were significantly increased
by the pretreatment with bucillamine as compared with cisplatin alone at 12 h. (b) Cell lysates were electrophoresed through an
SDS-polyacrylamide gel and subject to immunoblot analysis for HO-1, SOD1 and SOD2.
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significantly lower than those in the cisplatin alone (Po0.01).
ABR thresholds in bucillamine-alone were similar to those in
control with slightly lower values at 8 kHz and click (Po0.01).
These results indicate that bucillamine ameliorates cisplatin-
induced hair cell loss ex vivo as well as hearing impairments
in vivo.
DISCUSSION
Cisplatin is an effective chemotherapeutic agent that is cur-
rently used as the standard treatment for a variety of human
malignant neoplasms. However, clinical application of cisplatin
is limited because it often induces serious and irreversible
toxicity in bone marrow, gastrointestinal tract, kidney, cochlear
and nervous system.2,3 Previous studies using thiol-containing
compounds, including diethyldithiocarbamate, GSH, lipoic
acid, sodium thiosulfate and 4-methylthiobenzoic acid, have
evaluated the protective effects of these compounds against the
adverse effects of cisplatin.2,20,35 Additionally, the T-type
calcium channel blocker flunarizine and selenium-containing
compound ebselen have shown protective effects against
cisplatin-induced cytotoxicity and ototoxicity.19,21 However,
the mechanisms of cisplatin ototoxicity are yet to be fully
understood.
In this study, we examined whether bucillamine has a
protective effect against cisplatin. Pretreatment with bucilla-
mine markedly suppressed apoptotic cell death in cisplatin-
treated HEI-OC1 cells. In particular, bucillamine prevented
cisplatin-induced damages, including morphological changes,
MTT reduction, DNA laddering and nuclear fragmentation,
and decrease in the percentage of cells in the sub-G0/G1 phase
in a dose-dependent manner. Therefore, we demonstrate
for the first time that bucillamine can reduce cisplatin-
induced hair cell toxicity in auditory cells and the organ of
Corti. In addition, we also present in vivo evidence that
bucillamine prevents ABR threshold shifts induced by cisplatin
in Balb/C mice.
A number of studies suggest that caspase activation triggers
the apoptotic process in various types of cells. Caspase-3, an
apoptosis executioner, plays a pivotal role especially in the
terminal phase of apoptosis and is activated by other caspases,
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Figure 8 siRNA knockdown of HO-1 and SOD2 enzymes does not completely block the protective effects of bucillamine. (a) After
transfection of HEI-OC1 cell with double-stranded siRNA (HO-1, SOD2 or both), cells were pretreated with various concentrations of
bucillamine for 1 h followed by the addition of 20 μM cisplatin for 24 h. Then, cell viability was measured by MTT assays. (b) Cell lysates
were subject to immunoblot analysis with antibodies against pro-caspase-3 and active form of caspase-3. β-actin was used as a control.
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such as caspase-8 and caspase-9.36 Activated caspase-3 is
important for the occurrence of morphological changes, such
as DNA laddering and nuclear fragmentation in apoptotic
cells.37 Caspase-8 activity is initiated when FAS ligand or tumor
necrosis factors bind to cell-surface receptors that contain a
death domain, and lies upstream of caspase-3.38 Several reports
have demonstrated that cisplatin induced caspase-3 activation
in HEI-OC1 cells,39–41 which was virtually suppressed by
co-treating with various compounds, such as NF-κB inhibitors
(Bay 11–7085 and SN-50), polyphenolic compounds
(epicatechin) and immunosuppressors (JWH-015 and
HU210). A recent study showed that luteolin, acting as
antioxidant and anti-inflammatory reagent, suppressed activa-
tion of caspase-3, caspase-8 and caspase-9, and protects
cisplatin-induced apoptosis in auditory cells.39 In this study,
we showed that cisplatin significantly increased the active form
of caspase-3 and the activities of caspase-3 and -8 in auditory
cells, which was significantly inhibited by bucillamine pre-
treatment, suggesting that bucillamine effectively suppresses
cisplatin-induced cell death.
Like other cysteine derivatives, bucillamine is able to rapidly
enter into cells and interrupt redox signaling and oxidative
injury. Mazor et al.42 demonstrated that the antioxidant
capacity of bucillamine is higher than that of Trolox, ascorbic
acid or the thiol antioxidants GSH and NAC. In addition,
Horwitz and Sherman30 reported that bucillamine prevents
damages from peroxide or superoxide radicals in cultured adult
rat cardiac myocytes and substantially reduces myocardial
infarct size when administered during reperfusion. In rheuma-
toid arthritis patients, the antioxidant defense system is found
to be compromised, in which the activities of GSH peroxidase
and catalases, as well as the plasma concentrations of
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Figure 9 Bucillamine protects sensory hair cells from cisplatin in rat primary organ of Corti explants and prevents hearing loss in adult
mice. (a) Organ of Corti explants were dissected into three parts—basal, middle and apex turns—and treated with 20 μM cisplatin alone,
2mM bucillamine or cisplatin for 30 h. Cultures were stained with tetramethylrhodamine isothiocyanate-conjugated phalloidin and then
observed under a fluorescence microscope. (b) Auditory-brainstem-evoked response (ABR) thresholds were measured 3 days after i.p.
injection of cisplatin only (back bar, n=5), cisplatin plus bucillamine (hatch bar, n=5), bucillamine only (dot bar, n=5) and control
(saline) only (white bar, n=5). (c) Click thresholds were measured using the same mice groups in (b). ABR threshold changes were
compared with the basal level in the control mice injected with saline. Values are shown as the mean± s.e.m. * Indicates significant
(Po0.05) compared with the control (saline) group.
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β-carotene, vitamin E and reduced GSH, are significantly
decreased compared with those in healthy controls.43,44 In
addition, several reports showed that cisplatin exerts its renal
and cochlear toxicity by generating ROS and interfering with
the antioxidant defense system. Accordingly, thiol-containing
compounds (for example, diethyldithiocarbamate, GSH and
NAC) and the antioxidant enzymes (for example, catalase and
SOD) have been found to be nephroprotective and otoprotec-
tive against cisplatin-induced GSH depletion and GSH perox-
idase inactivation in cochlear tissues.3,14,45 In this study, we
showed that the protective effects of bucillamine against
cisplatin were achieved through the reduction of free radicals,
including hydroxyl radicals, NOs and superoxide anions,
indicating that bucillamine acts as a potent antioxidant against
cisplatin-induced ROS and reactive nitrogen species in
auditory cells.
The transcription factor Nrf2 binds antioxidant response
elements and regulates phase II detoxifying and antioxidant
genes.46 A recent study has demonstrated that bucillamine
induces GSH biosynthesis via Nrf2 activation in murine
Hepa1-6 and human HepG2 hepatoblastoma cells where the
GCLC, the rate-limiting enzyme of GSH biosynthesis and the
multidrug-resistance-associated protein (Mrp2) were induced
by Nrf2.33 We found that knockdown of HO-1 and SOD2
weakly increased cytotoxicity in cisplatin-induced cells com-
pared with cisplatin-alone-treated cells. However, western blot
analysis indicates that active caspase-3 levels were not increased
in cells transfected with siHO-1, siSOD2 or both, compared
with cisplatin alone. Although Nrf2 activation by bucillamine
induces HO-1 and SOD2 expression, these antioxidant
enzymes may have a partial role in bucillamine-mediated
protective effects.
GSH acts as a free radical scavenger, and intracellular GSH
participates in the metabolism and detoxification of electro-
philic drugs, antioxidant defense, maintenance of thiol redox
status and modulation of cell proliferation.47 In the present
study, we demonstrated that bucillamine significantly induces
the GSH synthesis enzymes, including γ-GCS subunits (GCLC
and GCLM) and GSS, via Nrf2 transactivation, which then
results in the increase of intracellular GSH contents in auditory
cells. Therefore, our study suggests that bucillamine possesses
excellent antioxidant properties in vitro, which may render the
compound suitable for therapeutic use in diseases resulting
from oxidative damages.
Ex vivo culture of the organ of Corti has been a useful model
for studying cisplatin- or aminoglycoside-induced toxicity and
otoprotective molecule screening.7 In the inner ear, cisplatin
application causes sensorineural hearing loss through apoptosis
of the cochlear hair cells and the spiral ganglion neurons.48 The
most prominent change observed in the cochlea after cisplatin
administration consists of loss of OHCs which progresses from
basal to apex in the cochlea turn. Cisplatin ototoxicity is not
limited to the auditory hair cells but also affects the auditory
neuron, the stria vascularis and the supporting cells of the
organ of Corti.49,50 In particular, supporting cells (Deiter's
cells) appeared more sensitive than OHCs, and structural
malformation of the supporting cell preceded detectable
changes in OHCs.51 Several studies with thiol-containing
antioxidants, such as NAC, GSH ester, diethyldithiocarbamate,
lipoic acid and sodium thiosulfate, have proposed the advan-
tages of otoprotective agents to reduce the adverse effects of
cisplatin on auditory functions.7,52–54 In the current study, we
tested the otoprotective role of bucillamine in cisplatin-treated
Balb/C mice, and found that bucillamine protects against
cisplatin-induced ototoxicity, which was evidenced by reducing
ABR threshold shifts at all frequencies. Several reports
demonstrated that a variety of antioxidant agents, including
D-methionine,55 NAC,56 sodium thiosulfate,57 thiourea,58
diethyldithiocarbamate8 and 4-methylthiobenzoic acid,8 signif-
icantly inhibited acute cochlear ototoxicity and markedly
reduced ABR thresholds in cisplatin-treated animals. Addition-
ally, ebselen pretreatment eliminated ABR threshold shift
and significantly reduced the pathologic consequences upon
cisplatin treatment8,19,52,59 and noise exposure60,61 in animals.
In the current study, we first investigated the anti-apoptotic,
antioxidant and otoprotective effects of bucillamine adminis-
tered with cisplatin in HEI-OC1 cells in cultured organ of Corti
and mice in vivo. Because ototoxicity and cytotoxicity caused
by cisplatin is mainly dependent on the depletion of intracel-
lular antioxidants in auditory cells and the cochlea, our results
strongly suggest that bucillamine possesses scavenging, antiox-
idant and anti-inflammatory effects through elimination of free
radicals, induction of antioxidant enzymes and increase in
intracellular GSH content. Therefore, our results together with
currently available information on the pharmacological appli-
cation of bucillamine, suggest that bucillamine might be a
potential agent in prevention of hearing loss caused by insults
of ROS challenges.
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